Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alcon Inc. Ordinary Shares (NY:ALC)

94.79 -0.96 (-1.00%)
Official Closing Price Updated: 7:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to... 
Via Talk Markets
US Stocks Trim Gains As Iran Mulls Attack On Israel; Gold, Oil Rally: What's Driving Markets Monday?
Wall Street turns negative due to geopolitical risks. Gold rises 1.5% and stocks edge higher. Scotiabank acquires minority stake in KeyCorp. 
Via Benzinga
Nasdaq, S&P 500 Futures Climb After Volatile Week As Traders Eye Inflation Data and Retail Earnings: Strategist Says Not CPI But This Data Can Give People Lot Of Conviction
The resilience of the market was in full display on Monday after last week’s “historical comeback” by the market. The major index futures traded higher, albeit by a modest magnitude. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Alcon Analysts Increase Their Forecasts Following Q1 Results
Via Benzinga
Alcon Inc. (NYSE: ALC) Records 52-Week High Tuesday Morning
Via Investor Brand Network
What 6 Analyst Ratings Have To Say About Alcon
Via Benzinga
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson has beaten earnings per share in more than 10 straight quarters. Will the trend continue in Q2? 
Via Benzinga
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
From Alcon Inc. Investors
Via Business Wire
ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q1 2024
ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Do You Have Your Eye On Vision Care Stocks?
For investors seeking stable and growing opportunities, eye care stocks are an attractive option. 
Via Talk Markets
MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?
Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news. 
Via Benzinga
The Latest Analyst Ratings for Alcon
Via Benzinga
Contact Lens Maker Alcon's Has New Growth Avenues, Analyst Upgrades Stock
Alcon's recent upgrades and promising opportunities, including the BELKIN Vision acquisition, expanding glaucoma treatment options, enhanced PanOptix IOL, and market advancements in China. 
Via Benzinga
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
2 Intriguing Medical Stocks To Buy For Steady Growth As Earnings Approach
Among the medical sector, Alcon and Prestige Consumer Healthcare are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14. 
Via Talk Markets
Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Results of 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population 
Via MarketBeat
Alcon Publishes Agenda for 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
From Alcon Inc. Corporate
Via Business Wire
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
From Alcon Inc. Investors
Via Business Wire
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month
"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins... 
Via Benzinga
Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: 'Innovation Is Key'
Innovation and digitalization have been in focus among ophthalmology majors. 
Via Benzinga
Good News For Dry Eye Disease Patients: Eye Care Focused Alcon's Treatment Shows Encouraging Benefit In Late-Stage Trials
Alcon (NYSE: ALC) released topline results from the two Phase 3 trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of  
Via Benzinga
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
From Alcon Inc. Investors
Via Business Wire
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Intel To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.